Cargando…

Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments

Despite recent advances in the systemic treatment of gastroesophageal cancers, prognosis remains poor. Comprehensive molecular analyses have characterized the genomic landscape of gastroesophageal cancer that has established therapeutic targets such as human epidermal growth factor receptor 2 (HER2)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gordon, Anderley, Johnston, Edwina, Lau, David K, Starling, Naureen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553429/ https://www.ncbi.nlm.nih.gov/pubmed/36238135 http://dx.doi.org/10.2147/OTT.S282718

Ejemplares similares

Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives
por: Davidson, Michael, et al.
Publicado: (2016)

Targeted Therapies and Developing Precision Medicine in Gastric Cancer
por: Pihlak, Rille, et al.
Publicado: (2023)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

Current progress in cancer treatment by targeting FGFR signaling
por: Du, Sicheng, et al.
Publicado: (2023)

Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas
por: Jomrich, Gerd, et al.
Publicado: (2019)

Targeting the immune milieu in gastrointestinal cancers
por: Turkes, Fiona, et al.
Publicado: (2020)

FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape
por: Klempner, Samuel J., et al.
Publicado: (2019)

Optimising Multimodality Treatment of Resectable Oesophago-Gastric Adenocarcinoma
por: Suwaidan, Ali Abdulnabi, et al.
Publicado: (2022)

Targeted therapies for gastroesophageal cancers
por: Hsu, Andrew, et al.
Publicado: (2020)

FGFR-TKI resistance in cancer: current status and perspectives
por: Yue, Sitong, et al.
Publicado: (2021)

Relevance of Position and Movement of the Gastroesophageal Junction in Gastroesophageal Reflux Disease
por: Lee, Yeong Yeh
Publicado: (2013)

Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases
por: Zhou, Zhen, et al.
Publicado: (2021)

Biological Significance and Targeting of the FGFR Axis in Cancer
por: Chioni, Athina-Myrto, et al.
Publicado: (2021)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer
por: Yang, Ying, et al.
Publicado: (2020)

Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations
por: Lima, Nadia Carvalho, et al.
Publicado: (2020)

Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy
por: Wang, Zechen, et al.
Publicado: (2023)

Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies
por: Butters, Oliver, et al.
Publicado: (2019)

Relevance of Position and Movement of the Gastroesophageal Junction in Gastroesophageal Reflux Disease: Author's Reply
por: Hong, Su Jin
Publicado: (2013)

Role of erlotinib in the management of pancreatic cancer
por: Starling, Naureen, et al.
Publicado: (2006)

Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling
por: Xiao, Jin-Fen, et al.
Publicado: (2021)

An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers
por: Mahe, Mélanie, et al.
Publicado: (2018)

FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2020)

Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing
por: Hyung, Sujin, et al.
Publicado: (2022)

Current Pharmacological Management of Gastroesophageal Reflux Disease
por: Wang, Yao-Kuang, et al.
Publicado: (2013)

Current Trends in the Management of Gastroesophageal Reflux Disease
por: Sandhu, Dalbir S., et al.
Publicado: (2018)

Clinical development and management of adverse events associated with FGFR inhibitors
por: Subbiah, Vivek, et al.
Publicado: (2023)

Targeting FGFR Pathways in Gastrointestinal Cancers: New Frontiers of Treatment
por: Ratti, Margherita, et al.
Publicado: (2023)

Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors
por: Casadei, Chiara, et al.
Publicado: (2019)

Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer
por: Turkington, R C, et al.
Publicado: (2014)

Targeted therapy in gastroesophageal cancers: past, present and future
por: Woo, Janghee, et al.
Publicado: (2015)

Editorial: Novel Molecular Targets and Treatments for Gastroesophageal Cancer
por: Lam, Alfred King-yin, et al.
Publicado: (2022)

FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes
por: Furugaki, Koh, et al.
Publicado: (2023)

Expression and clinical significance of FGFR1 and FGFR2 in laryngeal squamous cell carcinoma
por: Hu, Mengdie, et al.
Publicado: (2022)

The evolving immunotherapeutic landscape in advanced oesophagogastric cancer
por: Flynn, Michael, et al.
Publicado: (2018)

Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer
por: Lazo De La Vega, Lorena, et al.
Publicado: (2022)

Contemporary Tailored Oncology Treatment of Biliary Tract Cancers
por: Turkes, Fiona, et al.
Publicado: (2019)

Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the Prostate and Prostate Cancer
por: Wang, Cong, et al.
Publicado: (2019)

Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis
por: Zhang, Jinglin, et al.
Publicado: (2019)

Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers
por: Chuang, Jeremy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o72stceo742kjcp422ju145od4